Association of baseline tissue biomarkers with response to glofitamab. Box plots demonstrate CD20 H score (immunohistochemistry; n = 59) (A) and percentage of total CD8⁺ T cells (out of total cells in tumor area; immunofluorescence; n = 51) (B) in baseline tumor biopsy specimens in relation to the best overall response (BOR) categories. P values >.05. In panel A, images represent H scores of 300 (i), 175 (ii), and 59 (iii). Statistical analyses were performed for CR vs PR/stable disease (SD)/progressive disease (PD) and adjusted for log(glofitamab dose) and IPI category.